THREE-YEAR CLINICAL RESULTS OF PATIENTS RANDOMIZED TO 3 OR 12 MONTHS OF DUAL ANTIPLATELET AFTER ENDEAVOR ZOTAROLIMUS-ELUTING STENT IMPLANTATION IN OPTIMIZE

Autor:	Roberto Botelho, Marco Antonio Perin, George César Ximenes Meireles, Ricardo Costa, Eduardo L. Nicolela, José Armando Mangione, André Labrunie, Deepak L. Bhatt, Fausto Feres, Hélio José Castello, Fernando Devito, Alexandre Abizaid, José Antonio Marin-Neto, Décio Salvadori, Joao De Paula
Rok vydání:	2016
Předmět:	medicine.medical_specialty business.industry Daily practice medicine Zotarolimus eluting stent In patient Long term therapy Cardiology and Cardiovascular Medicine business Surgery
Zdroj:	Journal of the American College of Cardiology. 67:189
ISSN:	0735-1097
DOI:	10.1016/s0735-1097(16)30190-5
Popis:	Previous studies have suggested that short-term dual antiplatelet therapy (DAPT) (3-6 months) is non-inferior to long term therapy (≥12 months) in patients treated with new generation drug-eluting stents in daily practice. However, the very long-term follow-up is still unknown. The OPTIMIZE trial
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::792639dd1dde02ef03856a777f347fe3 https://doi.org/10.1016/s0735-1097(16)30190-5 Zobrazit plný text záznamu